Return to ads
All categories
Bapineuzumab

Bapineuzumab

Posted by
Posting ads for 49 years
Johnson & Johnson's (JNJ) $1.5 billion bet to share rights to Elan Corp.'s (ELN) experimental Alzheimer's-disease drugs seems reasonable considering it's a relatively small amount for J&J - and the payoff could be big.

J&J, New Brunswick, N.J., would vault to the forefront of Alzheimer's research by gaining access to Elan's bapineuzumab, a drug that could generate annual sales approaching $6 billion by the end of next decade, estimated Credit Suisse analyst Catherine Arnold.

J&J would have to share the profits with both Elan and its development partner Wyeth (WYE) - which in turn is in the process of being ...



http://online.wsj.com/article/BT-CO-20090702-709974.html
Reply to this ad
Recently viewed ads
Saved ads
Please log in to browse your saved adverts or sign up if you don't have an account yet.
Popular Stuff